PET scan test for bladder cancer using a targeted tracer
Treatments studied
Part of Cancer clinical trials.
This trial studies a special PET/CT scan tracer that is designed to bind to a protein (Nectin-4) found in some bladder cancers. It aims to help doctors see and stage tumors more clearly, which could improve diagnosis and treatment planning.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18 to 75 years old
- A clinician recommends you get a PET/CT scan for bladder cancer staging
- You have at least one measurable tumor spot on scans (doctors can track it)
- Heart function should be normal, and you should be expected to live at least 12 weeks
- If you can become pregnant: you must have a negative pregnancy test and agree to birth control during the study and for 3 months after
- You must be able to lie flat for about 30 minutes and be able to cooperate with the scan
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses a special PET scan to look for a protein called Nectin-4 in tumors like bladder, breast, and lung cancer. The goal is to see if this imaging can help better detect or monitor these cancers.
This study uses a special PET/CT scan (called 68Ga-NYM096) to see if it can help find different types of cancer. The scan may help doctors get clearer pictures of where cancer is in your body.
This trial uses a special PET/CT scan to see if your bladder cancer has HER2 proteins, which can help predict how well you will respond to a targeted antibody-drug conjugate treatment. It is for people with advanced bladder cancer who have already tried certain standard therapies.
This trial is testing a new radioactive imaging agent that targets a protein called Nectin-4, which is often found on lung tumors. The scan will help doctors see if the tumor is visible and how it spreads, which may guide better treatment decisions for lung cancer patients.
This trial studies how well a specific PET/CT scan using a radioactive tracer can detect or evaluate cancers. It may help doctors see where cancer is in the body more clearly.
This study tests a new type of PET scan (a specialized imaging test) that may better detect certain cancers by looking for a specific marker found on many tumor types. The scan uses a new tracer called 18F-T2 to help doctors see cancer more clearly.
Hear when a new Urothelial Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.